The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor

T Calandra, J Bernhagen, R A Mitchell, R Bucala, T Calandra, J Bernhagen, R A Mitchell, R Bucala

Abstract

For over 25 years, the cytokine known as macrophage migration inhibitory factor (MIF) has been considered to be a product of activated T lymphocytes. We recently identified the murine homolog of human MIF as a protein secreted by the pituitary in response to endotoxin administration. In the course of these studies, we also detected MIF in acute sera obtained from endotoxin-treated, T cell-deficient (nude), and hypophysectomized mice, suggesting that still more cell types produce MIF. Here, we report that cells of the monocyte/macrophage lineage are an important source of MIF in vitro and in vivo. We observed high levels of both preformed MIF protein and MIF mRNA in resting, nonstimulated cells. In the murine macrophage cell line RAW 264.7, MIF secretion was induced by as little as 10 pg/ml of lipopolysaccharide (LPS), peaked at 1 ng/ml, and was undetectable at LPS concentrations > 1 microgram/ml. A similar stimulation profile was observed in LPS-treated peritoneal macrophages; however, higher LPS concentrations were necessary to induce peak MIF production unless cells had been preincubated with interferon gamma (IFN-gamma). In RAW 264.7 macrophages, MIF secretion also was induced by tumor necrosis factor alpha (TNF-alpha) and IFN-gamma, but not by interleukins 1 beta or 6. Of note, MIF-stimulated macrophages were observed to secrete bioactive TNF-alpha. Although previously overlooked, the macrophage is both an important source and an important target of MIF in vivo. The activation of both central (pituitary) and peripheral (macrophage) sources of MIF production by inflammatory stimuli provides further evidence for the critical role of this cytokine in the systemic response to tissue invasion.

References

    1. J Neuroimmunol. 1992 Jul;39(1-2):91-100
    1. Endocrinology. 1957 Sep;61(3):300-8
    1. J Exp Med. 1964 Nov 1;120:721-32
    1. J Interferon Res. 1987 Apr;7(2):165-71
    1. Science. 1985 Aug 30;229(4716):869-71
    1. Scand J Immunol. 1986 Dec;24(6):739-43
    1. Nature. 1987 Dec 17-23;330(6149):662-4
    1. J Immunol. 1985 Jan;134(1):305-9
    1. J Clin Invest. 1987 Feb;79(2):319-26
    1. J Infect Dis. 1989 Feb;159(2):195-204
    1. J Immunol. 1985 Dec;135(6):3972-7
    1. J Exp Med. 1985 May 1;161(5):984-95
    1. J Exp Med. 1971 Jun 1;133(6):1356-76
    1. J Exp Med. 1988 Feb 1;167(2):570-81
    1. N Engl J Med. 1988 Jun 9;318(23):1481-6
    1. Chest. 1991 Jan;99(1):169-75
    1. Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1272-5
    1. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7522-6
    1. J Immunol. 1979 Apr;122(4):1228-36
    1. J Exp Med. 1973 Feb 1;137(2):275-90
    1. Cell Immunol. 1992 Dec;145(2):372-9
    1. J Exp Med. 1991 Feb 1;173(2):357-65
    1. Mol Cell Biol. 1992 Sep;12(9):3919-29
    1. Lancet. 1988 Mar 19;1(8586):605-9
    1. Science. 1987 Oct 23;238(4826):522-4
    1. Proc Natl Acad Sci U S A. 1966 Jul;56(1):72-7
    1. Science. 1986 Oct 24;234(4775):470-4
    1. Nature. 1993 Oct 21;365(6448):756-9
    1. J Immunol. 1975 Sep;115(3):781-6

Source: PubMed

Подписаться